Takeshi Namekawa1, Takanobu Utsumi2, Tomoaki Tanaka3, Mayuko Kaga1, Hidekazu Nagano3, Takashi Kono3, Koji Kawamura1, Naoto Kamiya4, Takashi Imamoto1, Hiroyoshi Suzuki4, Tomohiko Ichikawa1. 1. Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan. 2. Department of Urology, Toho University Sakura Medical Center, Shimoshizu 564-1, Sakura-Shi, Chiba, 285-8741, Japan. takanobu.utsumi@med.toho-u.ac.jp. 3. Department of Clinical Cell Biology, Graduate School of Medicine, Chiba University, Chiba, Japan. 4. Department of Urology, Toho University Sakura Medical Center, Shimoshizu 564-1, Sakura-Shi, Chiba, 285-8741, Japan.
Abstract
BACKGROUND: Laparoscopic adrenalectomy has been established as a standard surgical method for unilateral primary aldosteronism. Meanwhile, the background characteristics of the patients undergoing adrenalectomy have changed over the last 20 years. The aim of this study was to investigate the changes in hypertension cure rates after laparoscopic adrenalectomy during the last two decades. METHODS: This retrospective clinical study included 176 patients who underwent unilateral laparoscopic adrenalectomy for primary aldosteronism from 1995 to 2015. The patients were divided into two groups by decade. The patients' baseline characteristics and the hypertension cure rates were compared between the two groups. Additionally, the values were re-examined based on predictive model predicting postoperative hypertension cure. RESULTS: The hypertension cure rate decreased significantly from 51.8 to 31.1%. The following variables were significantly different between the two groups: age, sex, body mass index, history of diabetes mellitus, preoperative systolic and diastolic blood pressures, potassium level, and plasma renin activity. CONCLUSIONS: This study showed that the number of patients with unfavorable conditions for hypertension cure after adrenalectomy has recently increased. The treatment goal for primary aldosteronism is not only to cure the hypertension but also to prevent organ disorders due to inappropriate aldosterone levels. Therefore, we recommend laparoscopic adrenalectomy for unilateral primary aldosteronism, even if hypertension is not always cured postoperatively. However, clinicians need to fully explain the postoperative hypertension outcomes to primary aldosteronism patients.
BACKGROUND: Laparoscopic adrenalectomy has been established as a standard surgical method for unilateral primary aldosteronism. Meanwhile, the background characteristics of the patients undergoing adrenalectomy have changed over the last 20 years. The aim of this study was to investigate the changes in hypertension cure rates after laparoscopic adrenalectomy during the last two decades. METHODS: This retrospective clinical study included 176 patients who underwent unilateral laparoscopic adrenalectomy for primary aldosteronism from 1995 to 2015. The patients were divided into two groups by decade. The patients' baseline characteristics and the hypertension cure rates were compared between the two groups. Additionally, the values were re-examined based on predictive model predicting postoperative hypertension cure. RESULTS: The hypertension cure rate decreased significantly from 51.8 to 31.1%. The following variables were significantly different between the two groups: age, sex, body mass index, history of diabetes mellitus, preoperative systolic and diastolic blood pressures, potassium level, and plasma renin activity. CONCLUSIONS: This study showed that the number of patients with unfavorable conditions for hypertension cure after adrenalectomy has recently increased. The treatment goal for primary aldosteronism is not only to cure the hypertension but also to prevent organ disorders due to inappropriate aldosterone levels. Therefore, we recommend laparoscopic adrenalectomy for unilateral primary aldosteronism, even if hypertension is not always cured postoperatively. However, clinicians need to fully explain the postoperative hypertension outcomes to primary aldosteronism patients.
Authors: Gian Paolo Rossi; Marlena Barisa; Bruno Allolio; Richard J Auchus; Laurence Amar; Debbie Cohen; Christoph Degenhart; Jaap Deinum; Evelyn Fischer; Richard Gordon; Ralph Kickuth; Gregory Kline; Andre Lacroix; Steven Magill; Diego Miotto; Mitsuhide Naruse; Tetsuo Nishikawa; Masao Omura; Eduardo Pimenta; Pierre-François Plouin; Marcus Quinkler; Martin Reincke; Ermanno Rossi; Lars Christian Rump; Fumitoshi Satoh; Leo Schultze Kool; Teresa Maria Seccia; Michael Stowasser; Akiyo Tanabe; Scott Trerotola; Oliver Vonend; Jiri Widimsky; Kwan-Dun Wu; Vin-Cent Wu; Achille Cesare Pessina Journal: J Clin Endocrinol Metab Date: 2012-03-07 Impact factor: 5.958
Authors: H Go; M Takeda; H Takahashi; T Imai; T Tsutsui; T Mizusawa; T Nishiyama; H Morishita; Y Nakajima; S Sato Journal: J Laparoendosc Surg Date: 1993-10
Authors: E Born-Frontsberg; M Reincke; L C Rump; S Hahner; S Diederich; R Lorenz; B Allolio; J Seufert; C Schirpenbach; F Beuschlein; M Bidlingmaier; S Endres; M Quinkler Journal: J Clin Endocrinol Metab Date: 2009-02-03 Impact factor: 5.958
Authors: Wessel M C M Vorselaars; Sjoerd Nell; Emily L Postma; Rasa Zarnegar; F Thurston Drake; Quan-Yang Duh; Stephanie D Talutis; David B McAneny; Catherine McManus; James A Lee; Scott B Grant; Raymon H Grogan; Minerva A Romero Arenas; Nancy D Perrier; Benjamin J Peipert; Michael N Mongelli; Tanya Castelino; Elliot J Mitmaker; David N Parente; Jesse D Pasternak; Anton F Engelsman; Mark Sywak; Gerardo D'Amato; Marco Raffaelli; Valerie Schuermans; Nicole D Bouvy; Hasan H Eker; H Jaap Bonjer; N M Vaarzon Morel; Els J M Nieveen van Dijkum; Otis M Vrielink; Schelto Kruijff; Wilko Spiering; Inne H M Borel Rinkes; Gerlof D Valk; Menno R Vriens Journal: JAMA Surg Date: 2019-04-17 Impact factor: 14.766
Authors: Wessel M C M Vorselaars; Dirk-Jan van Beek; Emily L Postma; Wilko Spiering; Inne H M Borel Rinkes; Gerlof D Valk; Menno R Vriens Journal: World J Surg Date: 2019-10 Impact factor: 3.352